(Total Views: 416)
Posted On: 01/07/2022 11:49:11 AM
Post# of 156572
Re: Shelly2626 #114155
Yes and actual compelling data from a blinded trial hitting P values will move the needle. We shouldn’t have reported on the 350 mg open label. The market only cares about real results.
So I believe if the 700 mg NASH results are good we could see a increase in the SP which we need if we are going to start to sell the 200 million shares soon to keep us afloat.
So I believe if the 700 mg NASH results are good we could see a increase in the SP which we need if we are going to start to sell the 200 million shares soon to keep us afloat.
(0)
(0)
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Watchman Oversight Program
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Watchman Oversight Program
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
